The (IDH1) R132H peptide vaccine targets a frequently occurring mutation in the IDH1 gene found primarily in lower grade gliomas, which is responsible for aberrant neural signaling and glioma progression [35]. The gene discussed is IDH1; the disease is central nervous system cancer.